Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05893108
Other study ID # CT0012023
Secondary ID
Status Not yet recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date March 30, 2024
Est. completion date October 30, 2024

Study information

Verified date November 2023
Source Gadjah Mada University
Contact Anggraini
Phone (+62) 0813-6300-9995
Email yuniea2001@mail.ugm.ac.id
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objectives are to compare the efficacy of pre and post-treatment and between 5% losartan potassium loaded in ethosomal gel and 10 mg/ml triamcinolone acetonide injection based on the indicator score of The patient and observer scar assessment scale 3.0 (POSAS 3.0), degree of erythema and pigmentation, area size, thickness and density of human keloids.


Description:

After being informed about the study and the associated risks and benefits, participants will be randomly allocated to one of two groups, each consisting of 23 individuals. After being informed about the study and the associated risks and benefits, participants will be randomly allocated to one of two groups, each consisting of 23 individuals. One group will receive the topical application of 5% losartan gel, while the other will receive an injection of triamcinolone acetonide 10mg/ml. After being informed about the study and the associated risks and benefits, participants will be randomly allocated to one of two groups, each consisting of 23 individuals. To measure the subjective and objective changes that occur in the keloid before and after treatment, outcome assessors will be blinded. Measurements will be taken four times over the course of three months.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 46
Est. completion date October 30, 2024
Est. primary completion date September 30, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - keloid patients who came to the outpatient clinic of general hospital Syafira Pekanbaru during 2023-2024, - age is greater than or equal to 18 year - keloid scar than or equal to 25 cm2 - duration of keloids longer than or equal to 6 months - no drug interventions or not currently on keloid medications for the last two months. Exclusion Criteria: - subjects who do not understand the rubric of The patient and observer scar assessment scale (POSAS) and were not willing to participate - subjects with nodular keloids - subjects within antihypertensive therapy, pregnancy, malignancy, history of allergies, active skin lesions or bleeding in the keloid area. - subjects in the treatment of keloid within the last month.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ethosomal gel bearing losartan 5%
A pharmaceutical company with a good manufacturing practice certificate is developing ethosomal gel bearing losartan 5%
triamcinolone acetonide 10 mg/ml
intralesional injection

Locations

Country Name City State
Indonesia Rumah Sakit Syafira Pekanbaru Riau

Sponsors (2)

Lead Sponsor Collaborator
Yuni Eka Anggraini Gadjah Mada University

Country where clinical trial is conducted

Indonesia, 

References & Publications (6)

Bock O, Schmid-Ott G, Malewski P, Mrowietz U. Quality of life of patients with keloid and hypertrophic scarring. Arch Dermatol Res. 2006 Apr;297(10):433-8. doi: 10.1007/s00403-006-0651-7. Epub 2006 Mar 10. — View Citation

Elsaie ML. Update on management of keloid and hypertrophic scars: A systemic review. J Cosmet Dermatol. 2021 Sep;20(9):2729-2738. doi: 10.1111/jocd.14310. Epub 2021 Jul 3. — View Citation

Hedayatyanfard K, Ziai SA, Niazi F, Habibi I, Habibi B, Moravvej H. Losartan ointment relieves hypertrophic scars and keloid: A pilot study. Wound Repair Regen. 2018 Jul;26(4):340-343. doi: 10.1111/wrr.12648. Epub 2018 Oct 25. — View Citation

Khodaei B, Nasimi M, Nassireslami E, Seyedpour S, Rahmati J, Haddady Abianeh S, Motavalli Khiavi F. Efficacy of Topical Losartan in Management of Mammoplasty and Abdominoplasty Scars: A Randomized, Double-Blind Clinical Trial. Aesthetic Plast Surg. 2022 Oct;46(5):2580-2587. doi: 10.1007/s00266-022-02935-2. Epub 2022 May 25. — View Citation

Silva IMS, Assersen KB, Willadsen NN, Jepsen J, Artuc M, Steckelings UM. The role of the renin-angiotensin system in skin physiology and pathophysiology. Exp Dermatol. 2020 Sep;29(9):891-901. doi: 10.1111/exd.14159. — View Citation

Steckelings UM, Czarnetzki BM. The renin-angiotensin-system in the skin. Evidence for its presence and possible functional implications. Exp Dermatol. 1995 Dec;4(6):329-34. doi: 10.1111/j.1600-0625.1995.tb00056.x. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary The patient and observer scar assessment scale score (POSAS 3.0) The Patient and Observer Scar Assessment Scale 3.0 consists of sixteen items of the patient questionnaire (PSAS) with maximum and minimum values are 80 and 16, consecutively; and seven items of the observer questionnaire (OSAS) with maximum and minimum values are 35 and 7, consecutively. The lower score, the better result of the keloid. change from baseline the POSAS score at 4,8, and 12 weeks, consecutively.
Secondary Degree of erythema and hyperpigmentation The colors are taken using dermoscopy and quantifiably analysed using image analysis ImageJ change from baseline the degree of erythema and hyperpigmentation at 4, 8 and 12 weeks, consecutively.
Secondary the width of the keloid surface area (mm2) The surface area is taken by digital photography and quantifiably analysed using image analysis ImageJ change from baseline width of keloid surface area at 4, 8 and 12 weeks, consecutively.
Secondary The thickness of keloid (mm) The thickness of the keloids is assessed using high-frequency ultrasonography change from baseline thickness of keloid at 4, 8 and 12 weeks, consecutively.
Secondary The degree of pliability of keloid (durometer unit) The pliability of keloids is assessed using durometer shore type oo (Teclock Japan) change from baseline pliability at 4, 8 and 12 weeks, consecutively.
See also
  Status Clinical Trial Phase
Recruiting NCT02923596 - Retrospective Study of Keloid Disorder N/A
Completed NCT02922972 - Treatment of Keloid Scar by Autologous Platelet Rich Plasma Obtained With RgenKit-BCT N/A
Terminated NCT01478243 - Study of Psycho-Social Impact of Keloid N/A
Recruiting NCT01423383 - Epidemiology Study of Keloid N/A
Completed NCT03228693 - Gene Expression and Biomarker Profiling of Keloid Skin N/A
Not yet recruiting NCT04326959 - Implantation of Mesenchymal Stem Cell, Conditioned Medium, or Triamcinolone Acetonide for Keloid Phase 1/Phase 2
Recruiting NCT03312166 - Compressive Device to Prevent Keloïd Scars Recurrence [SCARWARS] N/A
Recruiting NCT02823236 - Efficacy of Intralesional Triamcinolone and 8% Topical Pirfenidone for Treatment of Keloid Scars Phase 3
Recruiting NCT04597060 - The Safety and Efficacy of Thermo-mechanical System for Fractional Ablation Associated Triamcinolone Acetonide Drug Delivery for the Treatment of Hypertrophic Scars and Keloids N/A
Completed NCT05939817 - The Effect of Intralesian Injection of Umbilical Cord Mesenchymal Stem Cells, Its Conditioned Medium, and Triamcinolone Acetonide on Type 1:3 Collagen Ratio and Interleukin-10 Levels in Keloid: A Randomised Controlled Trial Phase 4
Completed NCT05887804 - Comparison of Keloid Volume and Symptoms Reduction Between Intralesional Umbilical-Cord Mesenchymal Stem Cells, Its Conditioned Medium, and Triamcinolone Acetonide Injection as Keloid Therapy: A Randomised Controlled Trial Phase 4
Completed NCT03630198 - Pain Outcomes Following Intralesional Corticosteroid Injections Phase 4
Completed NCT04169438 - Pilot Study Investigating a Restorative Wound Care Cream Together With Petrolatum on Surgical Excisions N/A
Recruiting NCT01423981 - Web Based Investigation of Natural History of Keloid Disorder, an Online Survey N/A
Completed NCT01446770 - Evaluation of the Initial Safety and Efficacy of Keloid Lesions Treated With MF-4181 Phase 2
Recruiting NCT06138964 - Comparing the Effect of siSPARC Microneedle Patch Versus siSPARC+siLR4A Microneedle Patch on Post-surgical Scars Phase 3
Enrolling by invitation NCT05461157 - Preoperative Silicone Ointment and Wound Healing N/A
Not yet recruiting NCT04593706 - Comparison of the Efficacy of Different Steroids in the Treatment of Abnormal Scars (Keloids, Hypertrophic Scars) N/A
Active, not recruiting NCT04988022 - Dupilumab in the Treatment of Keloids Phase 4
Withdrawn NCT02546076 - Comparison of Dual-mode ER:YAG Laser in Patients With Long Keloid/Hypertrophic Scars Phase 2